In addition, it would be important to identify common fragile nodes of vimentin, NANOG and CD49f signalling in a more integrated manner in order to evaluate their interest as markers and or new therapeutic targets in triple negative breast cancer. This evidence concerns the gene VIM and triple-negative breast carcinoma.